Why did QuidelOrtho (QDEL) stock move recently?

On 8/25/2026, QuidelOrtho moved +3.9% — No specific company catalyst identified for the move; QDEL rose with broader market or sector sentiment following its post-earnings recovery after the August 6 guidance cut. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is QuidelOrtho (QDEL) overvalued or fairly valued?

MarketChacha shows QuidelOrtho's valuation in context — a forward P/E of about 9.8, a price-to-book of about 0.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is QuidelOrtho's revenue?

QuidelOrtho reported revenue of $2.7B for FY2025, with net profit of $-1.1B, per official filings.

What is the share price of QuidelOrtho (QDEL)?

QuidelOrtho last traded at $14.11 (+1.3% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

QuidelOrtho

QDEL · NYSE · Healthcare · United States

Snapshot

TickerQDEL

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees6,500

HeadquartersSan Diego, United States

Websitewww.quidelortho.com

Filings tracked18

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Who owns it

Insiders0.9%
Institutions99.1%
Public & other0.0%

340 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.34%
FMR, LLC10.74%
Newtyn Management, Llc9.66%
Vanguard Portfolio Management LLC6.03%
Neuberger Berman Group, LLC5.15%
Invesco Ltd.5.07%
American Century Companies Inc4.82%
Rubric Capital Management LP4.82%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 41.1 points over the period — profitability is trending down.

Net margin trend-0.3% → -41.5%

Margin has compressed by about 41.1 points over the period — profitability is trending down.

Return on equity-58.9%

Latest ROE of -58.9% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $665.6M · EPS 0.47

Est. earnings growth +2.1%

Next fiscal year

Rev $2.6B · EPS 1.44

Est. earnings growth +86.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.7B

Net margin

-41.5%

ROE

-58.9%

Revenue CAGR (2y)

-4.6%

EPS (FY2025)

-16.69

Net profit (FY2025)

$-1.1B

Ask MarketChacha about QDEL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
No specific company catalyst identified for the move; QDEL rose with broader market or sector sentiment following its post-earnings recovery after the August 6 guidance cut.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.7B	$-1.1B	-16.69	-41.5%	-58.9%
FY2024	$2.8B	$-2.1B	-30.54	-73.7%	-68.8%
FY2023	$3.0B	$-10.1M	-0.15	-0.3%	-0.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$630.9M	$-92.9M	-1.36	-14.7%
2026Q1	$619.8M	$-91.8M	-1.35	-14.8%
2025Q3	$699.9M	$-733.0M	-10.78	-104.7%
2025Q2	$613.9M	$-255.4M	-3.77	-41.6%
2025Q1	$692.8M	$-12.7M	-0.19	-1.8%
2024Q3	$727.1M	$-19.9M	-0.30	-2.7%
2024Q2	$637.0M	$-147.7M	-2.20	-23.2%
2024Q1	$711.0M	$-1.7B	-25.50	-239.9%
2023Q4	$744.0M	$-12.7M	-0.19	-1.7%
2023Q3	$665.1M	$-53.2M	-0.80	-8.0%
2023Q2	$846.1M	$48.8M	0.73	5.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/7/2026
8-K — Results of operations, Exhibits
SEC8/6/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/23/2026material
8-K — Shareholder vote results
SEC6/16/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/5/2026material
8-K — Results of operations, Exhibits
SEC4/15/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/24/2026material
10-K filing
SEC2/19/2026
8-K — Executive/director change
SEC2/13/2026material
8-K — Results of operations, Exhibits
SEC2/11/2026material
8-K — Executive/director change
SEC2/5/2026material

2025

8-K — Reg FD disclosure, Exhibits
SEC11/10/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/5/2025material
8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC8/21/2025material
10-Q filing
SEC8/6/2025
8-K — Results of operations, Exhibits
SEC8/5/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.